AI Drugmaker BioXcel Eyes $9.8M Investor Settlement
BioXcel Therapeutics Inc., an artificial intelligence-driven drugmaker, has reached a $9.8 million settlement with investors to resolve claims that the company and its top brass deceived them about compliance problems with...To view the full article, register now.
Already a subscriber? Click here to view full article